HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Phosphagenics licenses TPM® platform to Indian pharmaceutical company
Australian drug delivery technology company Phosphagenics Limited has licensed an injectable antibiotic product, harnessing its proprietary TPM® platform technology, to Agila Specialties Private Limited (Agila). Agila is a wholly owned subsidiary of the listed Indian pharmaceutical company, Strides Arcolab (Strides).

Agila has one of the largest steriles capacities in India and amongst the largest lyophilization (freeze drying) capacities in the world with its operations spread over nine world-class manufacturing facilities around the globe. The company is focused on developing and commercializing new products for key therapeutic markets targeting antiinfectives, oncology, central nervous system (CNS), gastro-intestinal (GI), ophthalmics and peptides.

Under the terms of the exclusive global license agreement, Phosphagenics will license the TPM® technology to Agila for its use in an antibiotic injectable product. Agila will be responsible for the development and pay the costs required to register and commercialize the product including all necessary clinical studies.

Phosphagenics will receive an upfront payment as well as undisclosed royalties based on net sales. The size of the antibiotic injectables market is several billion dollars annually.

Company CEO, Dr Esra Ogru, said this agreement demonstrates the versatility of the TPM® platform technology, paving the way for further opportunities in the injectable market.

 “Strides and its subsidiary, Agila, have state-of-the-art manufacturing capabilities and have had tremendous success in bringing new products to market. This will be the first time TPM® will be used in an injectable formulation.”

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy